Theranos Whistleblower Says AI Hype Could Give Fraudsters a New Opening
Tyler Shultz, the Theranos whistleblower, told The San Francisco Standard on October 30, 2026 that the current AI boom gives people who want to deceive investors a ready opening. His warning draws directly on the company that made his name.
Shultz's first job out of college was at Theranos. He became a key whistleblower on the company's blood-testing devices, which he helped expose as dangerously inaccurate. He was the first whistleblower to expose Theranos. He had met Elizabeth Holmes at Stanford. His grandfather, George Shultz, a former U.S. Secretary of State and Secretary of the Treasury, was a Theranos investor and board member.
The company's devices were deployed in Walgreens stores and delivered faulty results to real patients. Theranos reached a peak valuation of around $10 billion, even though its technology never actually worked. Much of its funding came from individual investors such as the DeVos and Walton families rather than from venture firms. The company did not share scientific information or evidence that its machines worked with potential investors, citing concerns about revealing trade secrets. A private-market audience that could not inspect the technology was asked to trust the story instead.
In the SF Standard interview, Shultz said the days of sending someone $100,000 after a thirty-minute coffee should be over. He said Holmes scaled that model to $100 million. He also said: "the only reason we're talking about Elizabeth Holmes right now is because she wants us to be talking about Elizabeth Holmes right now."
The core of his AI warning is about due diligence, the vetting an investor performs before committing money. Shultz said AI is hard to diligence because it is difficult to tell something truly unique and new from a ChatGPT wrapper, meaning a product built as a thin interface over a third-party model. Many startups in the current cycle are built on exactly that kind of foundation. An investor reviewing a pitch deck or a demo may find the distinction hard to test in the time available.
Holmes is now in federal prison. The documentary "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim, captures her final weeks before she entered prison. Shultz wrote a First Opinion essay for STAT News on October 19, 2026 about that film. On October 23, 2026 he appeared on CBS Mornings to discuss the deception surrounding Theranos's blood-testing technology. Earlier work on the story includes his 2022 audio memoir, "Thicker than Water," and HBO's 2019 documentary, "The Inventor: Out for Blood in Silicon Valley."
In my view, the most useful part of Shultz's argument is the mechanism, not the personalities. Theranos raised capital on claims that outside parties could not verify, and it withheld the evidence that would have allowed them to. The same structure, a product whose core differentiation is opaque to the person writing the check, is available to anyone building on a large language model today. Experienced investors already run technical diligence on model access, data rights and evaluation methods. The lesson Shultz points to is that the questions have to be asked before the money moves, and that a polished demo is not evidence of a working system.
Court proceedings, two documentaries, a memoir and a series of recent interviews have made the company's failures available to anyone who wants to study them. Shultz's willingness to keep returning to the case, including on television and in print this month, is one way that record stays in circulation.
In my view, that body of material is also a practical resource. It gives founders, investors and reporters a concrete checklist of what a credible technical claim looks like, and what an unverifiable one looks like.
